tiprankstipranks
Trending News
More News >

Cargo Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair analyst Sami Corwin downgraded Cargo Therapeutics (CRGX) to Market Perform from Outperform without a price target after the company announced the discontinuation of the Phase II FIRCE-1 clinical trial of its lead autologous CD22 CAR-T candidate firi-cel after an ad hoc analysis prompted by recent safety events found an unfavorable benefit/risk profile.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue